background: nonmelanoma skin cancer rates are increasing worldwide. mohs micrographic surgery and surgical excision (se) are the two treatment methods for this type of cancer. the current paper aims at determining and comparing the  cost-effectiveness of se and mohs micrographic surgery. materials and methods: the current study has a retrospective cohort design. a number of 630 patients sufferi...

EU Government brings cost of hepatitis C drug to V5,000 below list price, published 21st November 2014, PMLIVE website. http://www. pmlive.com/pharma_news/france_agrees_lowest_ sovaldi_pricing_in_eu_618661. Accessed January 22, 2016. 9. Messori A. Spend less on drug enforcement and more on treating hepatitis C, say campaigners [response]. BMJ website. http://www.bmj.com/ content/346/bmj.f3428/r...

Progressively increasing failure rates, high cost, poor bioavailability, poor safety, limited efficacy, and a lengthy design and testing process associated with cancer drug development have necessitated alternative approaches to drug discovery. Exploring established non-cancer drugs for anticancer activity provides an opportunity rapidly to advance therapeutic strategies into clinical trials. T...

background: although breast cancer imposes a considerable economic burden on high-income countries, there is limited knowledge about its economic burden in low- and middle-income countries (lmcs), including iran. in this study, we estimated the economic burden of breast cancer in iran in 2010. methods: we used the prevalence-based approach and estimated the direct and indirect costs of all brea...

BACKGROUND The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year. Survival rates for lung cancer are poor everywhere, but they appear to be better in the rest of the European Community and the USA than in the UK. Only about 5 per cent of people with lung cancer sur...

BACKGROUND In the past decade, many oncologic drugs have been approved that extend life and/or improve patients' quality of life. However, new cancer drugs are often associated with high price and increased medical spending. For example, in 2010, the average annual cost of care for breast cancer in the final stage of disease was reported to be $94,284, and the total estimated cost in the United...

background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...

BACKGOUND The Cancer Drugs Fund (CDF) has been the subject of controversy since its inception, with critics arguing that it creates a "backdoor" to the National Health Service (NHS), circumventing the National Institute for Health and Care Excellence and its health technology assessment program. Nonetheless, with its creation comes a new decision problem, how to best allocate resources among ca...